Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results

Diagnostic Microbiology and Infectious Disease
Shannon D PutnamRonald N Jones

Abstract

Telavancin was approved in the United States and Canada for the treatment of adult patients with complicated skin and skin-structure infections (cSSSI) caused by susceptible Gram-positive isolates. In this study, telavancin and comparator antimicrobial activities were determined against a total of 24,017 clinical isolates, including Staphylococcus aureus, coagulase-negative Staphylococcus spp. (CoNS), Enterococcus spp., and various Streptococcus spp. Overall, telavancin was highly active across all geographic regions for S. aureus (MIC(50/90), 0.12/0.25 microg/mL; 100.0% susceptible), CoNS (MIC(50/90), 0.12/0.25 microg/mL), vancomycin-susceptible Enterococcus faecalis (MIC(50/90), 0.25/0.5 microg/mL; 100.0% susceptible), Enterococcus faecium (MIC(50/90), 0.06/0.12 microg/mL), Streptococcus pneumoniae (MIC(50/90), < or =0.015/0.03 microg/mL), viridans group Streptococcus spp. (MIC(50/90), 0.03/0.06 microg/mL; 100.0% susceptible), and beta-hemolytic Streptococcus spp. (MIC(50/90), 0.03/0.12 microg/mL; 99.8% susceptible). Telavancin had potent activity against vancomycin-nonsusceptible, teicoplanin-susceptible (VanB) E. faecalis (MIC(50/90), 0.25/0.5 microg/mL) and E. faecium (MIC(50/90), 0.06/0.25 microg/mL). These in vitro resul...Continue Reading

References

Jun 17, 2004·Journal of Clinical Pharmacology·Steven BarriereJoel Morganroth
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Sharath S HegdeJ Kevin Judice
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·J P ShawS Barriere
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E StryjewskiUNKNOWN FAST Investigator Group
Jun 24, 2005·The Journal of Antimicrobial Chemotherapy·Sarah GanderRoger Finch
Jan 27, 2006·Antimicrobial Agents and Chemotherapy·Heather K SunDavid P Nicolau
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Martin E StryjewskiUNKNOWN FAST 2 Investigator Group
Jun 1, 2006·The Journal of Antimicrobial Chemotherapy·Noe ReyesSharath S Hegde
May 9, 2007·Antimicrobial Agents and Chemotherapy·José M MiróUNKNOWN Hospital Clínic Experimental Endocarditis Study Group
Jul 4, 2007·Antimicrobial Agents and Chemotherapy·W T M JansenD Milatovic
Feb 6, 2008·Diagnostic Microbiology and Infectious Disease·Brian T TsujiMichael J Rybak
Apr 30, 2008·Antimicrobial Agents and Chemotherapy·Kevin M KrauseBret M Benton
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E StryjewskiUNKNOWN Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study
Jan 22, 2009·The Journal of Antimicrobial Chemotherapy·Sharath S HegdeKevin M Krause
Apr 24, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R K C FongA Kurup
Apr 30, 2009·The Annals of Pharmacotherapy·Lisa CharneskiDonna Sym
Jun 6, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Robert E BurkeKathleen Gutierrez
Nov 17, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Louis D SaravolatzLeonard B Johnson

❮ Previous
Next ❯

Citations

Dec 5, 2012·The Journal of Antimicrobial Chemotherapy·Vincent Cattoir, Roland Leclercq
Nov 15, 2011·Expert Opinion on Pharmacotherapy·Ethan RubinsteinZeina A Kanafani
Jan 15, 2016·Expert Opinion on Drug Safety·Matteo Bassetti, Elda Righi
Aug 20, 2011·Diagnostic Microbiology and Infectious Disease·Rodrigo E MendesRonald N Jones
Jul 24, 2013·Expert Opinion on Pharmacotherapy·Jeffrey M RybakMichael J Rybak
Nov 15, 2011·Diagnostic Microbiology and Infectious Disease·Rodrigo E MendesRonald N Jones
Feb 11, 2015·Langenbeck's Archives of Surgery·Matteo Bassetti, Elda Righi
Dec 5, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G Ralph CoreySteven L Barriere
Oct 4, 2014·Clinical Microbiology Reviews·Karsten BeckerGeorg Peters
May 10, 2016·Expert Opinion on Drug Metabolism & Toxicology·Liapikou Adamantia, Torres Antoni
Dec 1, 2017·The Tohoku Journal of Experimental Medicine·Hiroki NamikawaHiroshi Kakeya
Dec 25, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Lamis R KaraouiElias B Chahine
Nov 11, 2014·Expert Review of Anti-infective Therapy·Sharath S Hegde, James W Janc
Feb 11, 2015·Expert Review of Anti-infective Therapy·Katie E BarberJason M Pogue
Jan 8, 2014·Expert Review of Anti-infective Therapy·Vincent Cattoir, Jean-Christophe Giard
Feb 26, 2021·Journal of Clinical Pharmacy and Therapeutics·Suraj ShresthaShyam Kumar Mishra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.